SCHEMBL3364922

SCHEMBL3364922

CCC(C)(C)c1ccc(S(=O)(=O)N(CC(=O)NN=C2C(=O)Nc3ccccc32)c2ccc(C)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
LMNA P02545 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HCRTR2 O43614 1/20 0.46
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 2/20 0.44
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
ALOX12 P18054 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTT P42858 1/20 0.44
OXTR P30559 3/20 0.43
AVPR1A P37288 1/20 0.43
TSHR P16473 1/20 0.42
MAPT P10636 1/20 0.41
RORC P51449 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3364917 1.00 ALDH1A1 (0.47) ALDH1A1LMNAKDM4EHCRTR2MEN1
SCHEMBL3367246 0.93 OXTR (0.51) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL3367251 0.93 OXTR (0.51) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL3366147 0.93 HCRTR2 (0.52) ALDH1A1LMNAKDM4EHCRTR2MEN1
SCHEMBL3366150 0.93 HCRTR2 (0.52) ALDH1A1LMNAKDM4EHCRTR2MEN1
SCHEMBL3366955 0.91 ALDH1A1 (0.54) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL3396501 0.91 ALDH1A1 (0.54) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL3366952 0.91 ALDH1A1 (0.54) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL3364599 0.87 ALDH1A1 (0.57) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL3366411 0.87 MEN1 (0.51) ALDH1A1LMNAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP claimed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US claimed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US claimed
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives OXTR, AVPR2, OPRL1 ALDH1A1 2629/4885LMNA 1852/4885KDM4E 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.